The global bioburden testing market will grow at highest pace owing to strict regulatory guidelines for bioburden control. Bioburden testing refers to the process of detecting and quantifying the microbial contaminants present in raw materials, components, and finished products within the biopharmaceutical industry. It plays a critical role in ensuring product purity and patient safety. The testing of in-process materials and finished drug products for microbial viability is required to validate sterile manufacturing processes. With increasing demand for biologics and stringent regulations regarding sterility, the need for effective bioburden testing is growing substantially.
The Global Bioburden Testing Market is estimated to be valued at US$ 1.40 BN in 2024 and is expected to exhibit a 13% CAGR over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Bioburden Testing Market Size are Charles River Laboratories International, Inc., SGS SA, Merck KGaA, Becton Dickinson and Company, Wuxi Apptec, North American Science Associates Inc., Nelson Laboratories, LLC, Biomérieux SA, Thermo Fisher Scientific and Pacific Biolabs. These players are focussing on new product launch, collaboration and expansion to strengthen their market position.
The growing demand for biopharmaceuticals and stringent regulatory requirements regarding sterility and bioburden control are the major factors driving the growth of the bioburden testing market. With increasing outsourcing of biomanufacturing and rising pipeline of biologics, the demand for bioburden testing from both pharmaceutical and biotechnology companies is increasing substantially.
Advancements in microbial detection technologies such as automated rapid microbiological methods, automated image analysis, and PCR-based methods are enhancing the sensitivity, speed, and throughput of bioburden testing. This is supporting the efficient evaluation of raw materials, components, and finished products.
Market Trends
The increasing adoption of continuous bioburden monitoring systems and real-time microbial detection tools allows for the consistent evaluation of manufacturing environments and rapid response to any potential issues. Rapid microbial identification techniques incorporating MALDI-TOF mass spectrometry or DNA sequencing are also gaining popularity.
Outsourcing of bioburden testing to premium third-party laboratories is growing owing to their testing expertise, flexibility in turn-around-times, and focus on analytical validation & documentation as per regulatory standards. This allows biopharma companies to focus on their core drug development activities.
Market Opportunities
The emerging markets in Asian countries offer significant growth opportunities for players in the bioburden testing market. This is attributed to rising biopharmaceutical manufacturing capabilities and strengthening regulatory oversight in these regions.
Integrating additional microbial identification capabilities with automated bioburden enumeration tools provides opportunities for development of comprehensive sample-to-result testing solutions. Such integrated platforms allow for efficient evaluation and monitoring of all critical process points.
Impact of COVID-19 on Bioburden Testing Market
The COVID-19 pandemic has significantly impacted the bioburden testing market globally. Bioburden testing procedures have become an integral part of the quality control requirements for manufacturing biologics to ensure their sterility, safety and efficacy. During the pandemic, the demand for upstream bioburden testing of raw materials and component supplies used in biopharmaceutical production surged to minimize supply chain risks. Stringent quality control checks were conducted at various stages of new drug development, manufacturing and packaging processes to avoid product contamination. There was increased focus on environmental monitoring and personnel training to establish reliable sterilization practices. The need for rapid sterility testing of personal protective equipment, medical devices and vaccines accelerated. Though lockdowns disrupted production and supply chains initially, demand picked up strongly in 2021 as large-scale vaccine manufacturing ramped up. To facilitate high-volume testing, automated monitoring systems and digital platforms were adopted. The bioburden testing market is expected to grow steadily in the coming years driven by ongoing pandemic preparedness activities and new therapeutic developments.
Geographical Regions with Highest Bioburden Testing Market Value
North America currently dominates the global bioburden testing market with the highest market share in terms of value, led by the US. This can be attributed to presence of many leading biopharmaceutical companies and Contract Research Organizations (CROs) in the region, along with stringent regulations enforced by regulatory bodies like the FDA. Growth opportunities also exist in Asia Pacific region, where China, India, Japan and South Korea are emerging as major hubs for outsourced biomanufacturing and generics production. Investments in this field are increasing in Asia to cater to rising local healthcare demands as well as act as alternative manufacturing bases to Western nations.
Fastest Growing Region in Bioburden Testing Market
Asia Pacific region is poised to witness the fastest growth in the global bioburden testing market during the forecast period. This growth can be accredited to expanding biopharmaceutical industry, increasing healthcare expenditures, rising awareness about quality control and favorable government policies supporting local life sciences sector in emerging Asian countries. Additionally, several global pharma companies are establishing manufacturing facilities in low-cost Asian nations like India and China for biosimilars and biologic drugs, driving augmented need for sterility and purity testing capabilities in these regions.
Get more insights on This Topic- Bioburden Testing Market
Explore More Articles - Carbon Offset Market
The Bioburden Testing Market research report provides the latest industry data, growth, key segments and future trends on the basis of the detailed study.
This market report also allows you to identify the future opportunity and growth rate of the leading segment based on regions and countries.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the bioburden testing market include Becton, Dickinson and Company, bioMérieux S.A., Charles River, Merck KGaA, NAMSA, Nelson Laboratories, LLC, Pacific BioLabs, SGS SA, Thermo Fisher Scientific, Inc. and WuXi App Tec.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Bioburden Testing Market Research Report" by requesting FREE Sample Copy athttps://www.valuemarketresearch.com/contact/bioburden-testing-market/download-sampleMarket DynamicsThe rapidly growing healthcare industry along with the technological advancements is primarily driving the market growth.
In addition to this, rising safety concern globally is further expected to boost market growth.
On the flip side, the high cost of laboratory instruments may limit market growth.The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis.
Bioburden Testing Market - HighlightsBioburden testing refers to an estimation of microbial load on a medical instrument, raw material, packaged goods among others.
Several factors such as rising medical spending, increasing food safety concerns and growing product recalls due to microbial contamination are projected to drive the growth of the market.
The Global Bioburden Testing Market is expected to register a CAGR of Approx.
9.15% during the forecast period of 2018–2023 with an estimated market value of USD 455 million.
Moreover, test reports and certificates tend to be different from one country to another which hampers international trade.
Therefore, in December 2017, International Organization for Standardization (ISO) published a new edition of ISO/IEC 17025 standard.
